Detalhe da pesquisa
1.
Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature.
Oncol Ther
; 10(1): 291-300, 2022 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-35066813
2.
KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population.
Front Oncol
; 12: 968064, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36452502
3.
Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC).
J Thorac Dis
; 14(4): 816-819, 2022 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-35572898